Clinical Trial

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion Dose (RCED) of FORX-428 as monotherapy.
Trial Details
NCT Number NCT07356453
Lead Sponsor FoRx Therapeutics AG
Conditions Advanced Solid Tumors
Enrollment 40 participants
Start Date 2025-07-22
Primary Completion 2027-06 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-21